Ma X, Liu Z, Ilyas I et al (2021) GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
In addition to weight reduction, the Phase 2 trial reported improvements in several cardiometabolic markers, including: Reductions in waist circumference Improvements in blood pressure Favourable changes in lipid profiles Reductions in fasting glucose and insulin resistance Increases in heart rate were also observed, consistent with findings seen with other incretin-based therapies These findings suggest that retatrutide may offer broader metabolic benefits beyond weight loss alone, which is particularly relevant for patients with obesity-related comorbidities such as type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), or elevated cardiovascular risk
It can be difficult for some people to meet their vitamin B12 requirements
[2][13] Unfortunately, due to the rise in popularity of these drugs for weight loss, there are reports of shortages occurring
This increased cAMP activated AMPK, enhanced oxidative decomposition of lipids, and inhibited de novo synthesis of fatty acids, inhibiting the development and progression of obesity and type 2 diabetes
,aspect=ignore)
